MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.60 (-3.02%)

Stability Price

Overvalued by 92.97%

Company Metrics

  • 13.83 P/E
  • 22.35 P/S
  • 5.16 P/B
  • -1.78 EPS
  • -5.97% Cash ROIC
  • 8.05 Cash Ratio
  • 0 / 0% Dividend
  • 1.02M Avg. Vol.
  • 1.08B Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


The Insider and Senior VP - Pharmaceutical Scie of Momenta Pharmaceuticals ... - May 22, 2015
Mr. John Bishop, the crucial Senior VP - Pharmaceutical Scie at Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 19.88 +0.57 2.95% has recently been connected with a transaction of 227 shares of the professional & scientific & and technical services's ...
Momenta Pharmaceuticals (MNTA): Heavy Pre-Market Activity -
Momenta Pharmaceuticals Inc (MNTA) Insider Selling : Richard P Shea Sells ... - Money Flow Index
Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Motley Fool - Apr 16, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM ... - MarketWatch
Notable Session Mover: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Vanguard Tribune - 13 hours ago
A notable mover in today's trading session is Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) as the stock opened the most recent session at 19.80 and at the time of writing the last Bid was at 19.08.
The President of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Craig ... - Apr 27, 2015
President, Craig Wheeler is the Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 19.24 -0.07 -0.36% 's insider which unloaded shares of Momenta Pharmaceuticals Inc, 51,667 to be exact. The shares were estimated based on $20.0, with the insider ...
Insider Selling: Ganesh Venkataraman Kaundinya Sells 34000 Shares of ... - Dakota Financial News
Insider Selling: Momenta Pharmaceuticals President Craig A. Wheeler Sells ... - The Legacy
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Apr 17, 2015
Momenta Pharmaceuticals Inc. (MNTA - Analyst Report) was a big mover last session, as the company saw its shares rise over 6% on the day.
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the ... - Nasdaq
John Bishop just Sold 493 shares of Momenta Pharmaceuticals, Inc. (NASDAQ ... - May 8, 2015
It was reported in a report that's submitted to the Security and Exchange Commission that John Bishop, who works for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 19.88 +0.57 2.95% , and currently serves as Senior VP - Pharmaceutical Scie performed ...
The Insider, John Bishop Sold 33625 Shares of Momenta Pharmaceuticals, Inc ... - May 13, 2015
The Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 19.88 +0.57 2.95% 's Senior VP - Pharmaceutical Scie, John Bishop, the insider made a sale of - 33,625 Momenta Pharmaceuticals Inc's shares, estimated based on $20.7 per share. The sold shares a ...
Stock Analysts Update on Momenta Pharmaceuticals Inc (NASDAQ:MNTA)
Markets Wired - Apr 17, 2015
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) price target raised to $24 from $16 at Leerink. Leerink raised its price target for Momenta Pharma to $24 following the “much anticipated” approval of generic Copaxone.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA FDA had approved Novartis ... - Inside Trade
Momenta Pharmaceuticals (MNTA) Showing Signs Of Perilous Reversal Today -
Momenta Pharmaceuticals (MNTA) Marked As A Dead Cat Bounce Stock - May 1, 2015
This is a clear sign of weakness within the company. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P ...
Earnings Preview: Gilead Sciences, Inc., Momenta Pharmaceuticals, Inc., and ...
Schaeffers Research (blog) - Apr 30, 2015
Among the stocks gearing up to report earnings are biotech firms Gilead Sciences, Inc. (NASDAQ:GILD) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), as well as blue chip Chevron Corporation (NYSE:CVX). Below, we'll take the pre-earnings ...